Everest is expanding to Manila Philippines
February 3, 2026

Everest Clinical Research to Expand Asia Pacific Operations with New Biometrics Team in the Philippines

Expansion will strengthen global biometrics delivery and support continued growth across the globe

TORONTO — February 3, 2026 –Everest Clinical Research, a leading full-service contract research organization (CRO) with deep biometrics foundations, announces the expansion of its Asia Pacific operations with the establishment of a new biometrics team in the Philippines. The company expects to hire approximately a dozen team members initially, including high-caliber statistical programmers and clinical data managers, to meet the needs of its growing global client base.

This expansion builds on Everest’s existing Asia Pacific presence, which includes established offices in Shanghai and Taipei, and further enhances the company’s ability to deliver high-quality, integrated biometrics services across the globe. The new Philippines-based team will work closely with Everest’s North American and Asia Pacific delivery teams, supporting a diverse portfolio of biotechnology and pharmaceutical clients in North America and around the world.

The Philippines expansion follows Everest’s recent success in biometrics talent growth in Poland, initiated in Q4 2025, underscoring the company’s continued global investment in scalable, best-in-class biometrics capabilities. Together, these strategic expansions reinforce Everest’s position as a growing global CRO with deep differentiated expertise in statistics and programming, clinical data management, and broader strategic and technology-enabled biometrics services.

To see the open positions in the Philippines, visit this link.

Recent Posts

Best CRO
Everest Clinical Research Named Finalist for Best Full-Service CRO Award
Everest Clinical Research acquires Firma Data Services
Everest Clinical Research Expands Global Biometrics Capabilities with Acquisition of Firma Clinical Research’s Data Services Business Unit
Planning for an ISS and ISE
The Top ISS and ISE Mistakes That Delay Regulatory Submissions
European Clinical Trial Strategy
Building a Smarter European Country Strategy for Your Next Oncology Study: Four Strategic Considerations
Outside of FDA Offices
One Pivotal Trial as the “New Default” for FDA Approval: Is FDA Really Changing Course?

Share This Post